How Biosimilar Competition Is Reshaping Biotech Stock Valuations Right Now

Biotech stocks are not moving in a vacuum. Behind many of the sector’s sharpest price swings lies a force that analysts have been tracking for years but that is now hitting with full intensity: biosimilar competition. As more blockbuster biologics lose patent protection and lower-cost alternatives flood the market, the financial consequences for brand-name manufacturers are becoming impossible to ignore — and the ripple effects are visible in trading patterns across the entire sector.

The stakes are enormous. Global biosimilar market revenues are projected to surpass $80 billion in the near term, driven by regulatory approvals in the United States, Europe, and emerging markets. For investors, understanding where biosimilar pressure is concentrated — and which companies are positioned to absorb or even benefit from it — has become one of the most consequential analytical tasks in biotech equity research.

Why Biosimilar Pressure Is Accelerating Now

The current wave of biosimilar competition is not simply a continuation of past trends. It reflects a convergence of factors that have matured simultaneously. The FDA’s biosimilar approval pipeline has become more efficient, reducing the time from application to market entry. At the same time, pharmacy benefit managers and hospital formulary committees are under intense cost pressure, making them far more willing to substitute biosimilars for originator biologics than they were even three years ago. The result is faster erosion of market share for legacy products than manufacturers originally modeled.

Consider the adalimumab market, where multiple biosimilar entrants have restructured pricing dynamics in ways that have materially impacted AbbVie’s revenue trajectory. That pattern is now repeating across therapeutic categories including oncology supportive care, ophthalmology, and autoimmune disease. Each new approval triggers a reassessment of the originator company’s long-range revenue forecasts — and by extension, its stock valuation multiple.

Smaller biotechs are not immune either. Companies that built their commercial strategies around a single biologic asset are particularly vulnerable. When biosimilar competition arrives earlier than projected, the compressed revenue window can make it nearly impossible to fund next-generation pipeline development, forcing dilutive capital raises or outright consolidation. Investors who track pipeline depth alongside patent expiry schedules are often able to identify these vulnerabilities before they surface in quarterly earnings calls.

Which Companies Are Turning the Threat Into an Opportunity

Not every biotech is on the wrong side of this shift. A growing number of companies have pivoted aggressively into biosimilar development itself, recognizing that manufacturing scale, regulatory expertise, and commercial relationships can generate durable revenue streams. Firms like Amgen, Samsung Bioepis, and Sandoz have built biosimilar portfolios that are now contributing meaningfully to top-line growth — a dynamic that is being rewarded with more stable earnings multiples even as originator-focused peers face compression.

Investors are also paying close attention to companies developing next-generation biologics that offer genuine clinical differentiation, creating higher regulatory and scientific barriers for biosimilar entrants. Subcutaneous formulations, extended half-life modifications, and combination biologic therapies represent strategies that can delay or reduce the impact of biosimilar competition by resetting the patent clock and improving patient adherence. When a company announces data supporting a differentiated formulation of an existing biologic, the market tends to respond positively — and that reaction is itself a signal of how seriously biosimilar risk is being priced into valuations.

The geographic dimension matters too. While U.S. biosimilar penetration has historically lagged Europe due to regulatory complexity and contracting dynamics, that gap is narrowing. Policy momentum around drug pricing reform has created additional incentive for payers to drive biosimilar adoption, and some analysts now estimate that U.S. biosimilar market share in key categories could reach European levels within the next several years. Companies with strong positions in markets where biosimilar uptake is still early may face a steeper repricing than their current stock prices reflect.

For biotech investors, the practical takeaway is that biosimilar competition can no longer be treated as a distant or theoretical risk. It is an active, accelerating force that is reconfiguring revenue models, redirecting R&D capital, and directly influencing which companies attract institutional money. The sector’s best-performing investors are those who have built frameworks to assess biosimilar exposure not just at the product level, but across the entire commercial and pipeline architecture of each company they follow. In a market where the next patent cliff is always approaching, that analytical edge is not optional — it is the price of informed participation.